Life sciences researchers need a host of tools to develop and test critical disease-treating drugs and therapies, from basic research to final product release. Primary cells, media, and reagents are all important for supporting preclinical and clinical pharmaceutical workflows for drug discovery and absorption, distribution, metabolism, excretion, and toxicity (ADMET) testing. In particular, scientists can use primary cells to build advanced 2D and 3D predictive models for liver, skin, vascular, and respiratory toxicities, striving to better understand the pharmacokinetics and metabolism of new compounds.

In this webinar, hosted by DDW and supported by Lonza, Kevin Grady and Manisha Nautiyal review how primary human cells and optimised media systems can be the building blocks for developing the next generation of predictive in vitro ADMET solutions.  

What you will learn:

• About Lonza’s primary cells and media systems for optimised toxicity testing
• How to evaluate toxicity in different physiological systems
• How to develop advanced, biologically-relevant models using a sophisticated portfolio of products and custom services
  
  A Q&A session follows the webinar presentation.

Watch the webinar on-demand now!